Genetics of dementia

Seminars in Neurology

Volumn 31, Issue 5, 2011, Pages 449-460

  Paulson, Henry L ^a,b   Igo, Indu ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Amyloid; dementia with Lewy bodies; frontotemporal dementia; genetic risk factors; neurodegeneration

Indexed keywords

ABC TRANSPORTER; APOENZYME; ATP BINDING CASSETTE TRANSPORTER A7; BRIDGING INTEGRATOR 1; CD2 ASSOCIATED PROTEIN; CD33 ANTIGEN; CLUSTERIN; COMPLEMENT COMPONENT C3B RECEPTOR; MEMBRANE SPANNING 4A; PHOSPHATIDYLINOSITOL BINDING CLATHRIN ASSEMBLY PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOPATHY; ARTICLE; CADASIL; CHOLESTEROL METABOLISM; CHROMOSOME 17; DIFFUSE LEWY BODY DISEASE; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ENDOCYTOSIS; ENVIRONMENT; FRAGILE X PREMUTATION TREMOR ATAXIA SYNDROME; FRONTOTEMPORAL DEMENTIA; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; HUNTINGTON CHOREA; IMMUNE SYSTEM; LIPID METABOLISM; POLYGLUTAMINOPATHY; PRION DEMENTIA; PRIONOPATHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPSE; SYNUCLEINOPATHY; TAUOPATHY; TDP 43 PROTEINOPATHY;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; DEMENTIA; DNA REPEAT EXPANSION; FRONTOTEMPORAL LOBAR DEGENERATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HUNTINGTON DISEASE; LEWY BODY DISEASE; MUTATION; PRION DISEASES;

EID: 84856145841     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0031-1299784     Document Type: Article

References (102)

1. Bertram L, Lill C M., Tanzi R E. The genetics of Alzheimer disease: back to the future. Neuron 2010 68 2 270-281
2. Van Broeckhoven C. The future of genetic research on neurodegeneration. Nat Med 2010 16 11 1215-1217
3. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet 2010 19 R1 R12-R20
4. Kim J, Basak J M., Holtzman D M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009 63 3 287-303
5. Green R C., Roberts J S., Cupples L A. et al, REVEAL Study Group. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med 2009 361 3 245-254
6. Ashe K H., Zahs K R. Probing the biology of Alzheimer's disease in mice. Neuron 2010 66 5 631-645
7. Kim D, Tsai L H. Bridging physiology and pathology in AD. Cell 2009 137 6 997-1000
8. Thinakaran G, Koo E H. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008 283 44 29615-29619
9. LaFerla F M. Pathways linking Abeta and tau pathologies. Biochem Soc Trans 2010 38 4 993-995
10. Ittner L M., Ke Y D., Delerue F et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010 142 3 387-397
11. Cruchaga C, Kauwe J S., Mayo K et al. SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet 2010 6 9 pii: e1001101
12. Fagan A M., Head D, Shah A R. et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 2009 65 2 176-183
13. Holtzman D M. Cerebrospinal fluid beta-amyloid 42, tau, and P-tau: confirmation now realization. Arch Neurol 2009 66 12 1552-1553
14. Hu W T., Chen-Plotkin A, Arnold S E. et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 2010 119 6 669-678
15. Jack C R. Jr, Knopman D S., Jagust W J. et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010 9 1 119-128
16. Jagust W J., Landau S M., Shaw L M. et al, Alzheimer's Disease Neuroimaging Initiative. Relationships between biomarkers in aging and dementia. Neurology 2009 73 15 1193-1199
17. Morris J C., Roe C M., Grant E A. et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009 66 12 1469-1475
18. Vemuri P, Wiste H J., Weigand S D. et al, Alzheimer's Disease Neuroimaging Initiative. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010 75 2 143-151
19. Sperling R A., Aisen P S., Beckett L A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 7 3 280-292
20. Bertram L, McQueen M B., Mullin K, Blacker D, Tanzi R E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007 39 1 17-23 (Pubitemid 46026496)
21. Colhoun H M., McKeigue P M., Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003 361 9360 865-872 (Pubitemid 36331853)
22. Harold D, Abraham R, Hollingworth P et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009 41 10 1088-1093
23. Lambert J C., Heath S, Even G et al, European Alzheimer's Disease Initiative Investigators. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009 41 10 1094-1099
24. Seshadri S, Fitzpatrick A L., Ikram M A. et al, CHARGE Consortium GERAD1 Consortium EADI1 Consortium. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010 303 18 1832-1840
25. Hollingworth P, Harold D, Sims R et al, Alzheimer's Disease Neuroimaging Initiative CHARGE consortium EADI1 consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011 43 5 429-435 10.1038/ng.803
26. Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molecular genetics: from past, to present, to future. Hum Mol Genet 2010 19 R1 R4-R11
27. Yerbury J J., Poon S, Meehan S et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 2007 21 10 2312-2322 (Pubitemid 47230661)
28. Kirszbaum L, Bozas S E., Walker I D. SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges. FEBS Lett 1992 297 12 70-76
29. Thambisetty M, Simmons A, Velayudhan L et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 2010 67 7 739-748
30. Calero M, Rostagno A, Frangione B, Ghiso J. Clusterin and Alzheimer's disease. Subcell Biochem 2005 38 273-298
31. Braskie M N., Jahanshad N, Stein J L. et al. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci 2011 31 18 6764-6770
32. Krych-Goldberg M, Atkinson J P. Structure-function relationships of complement receptor type 1. Immunol Rev 2001 180 112-122 (Pubitemid 32475753)
33. Zanjani H, Finch C E., Kemper C et al. Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord 2005 19 2 55-66 (Pubitemid 41073081)
34. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller A J., van Gool W A., Hoozemans J J. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 2006 113 11 1685-1695 (Pubitemid 44657664)
35. Rogers J, Li R, Mastroeni D et al. Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 2006 27 12 1733-1739 (Pubitemid 44572574)
36. Brouwers N, Van Cauwenberghe C, Engelborghs S et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 2011; March 15 [Epub ahead of print]
37. Tebar F, Bohlander S K., Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell 1999 10 8 2687-2702 (Pubitemid 29393520)
38. Koo E H., Squazzo S L. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem 1994 269 26 17386-17389 (Pubitemid 24218009)
39. Carey R M., Balcz B A., Lopez-Coviella I, Slack B E. Inhibition of dynamin-dependent endocytosis increases shedding of the amyloid precursor protein ectodomain and reduces generation of amyloid beta protein. BMC Cell Biol 2005 6 30
40. Harel A, Wu F, Mattson M P., Morris C M., Yao P J. Evidence for CALM in directing VAMP2 trafficking. Traffic 2008 9 3 417-429 (Pubitemid 351189000)
41. Sakamuro D, Elliott K J., Wechsler-Reya R, Prendergast G C. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet 1996 14 1 69-77 (Pubitemid 26301549)
42. Wigge P, McMahon H T. The amphiphysin family of proteins and their role in endocytosis at the synapse. Trends Neurosci 1998 21 8 339-344 (Pubitemid 28341961)
43. Meunier B, Quaranta M, Daviet L, Hatzoglou A, Leprince C. The membrane-tubulating potential of amphiphysin 2/BIN1 is dependent on the microtubule-binding cytoplasmic linker protein 170 (CLIP-170). Eur J Cell Biol 2009 88 2 91-102
44. Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb 2011 18 4 274-281
45. Ikeda Y, Abe-Dohmae S, Munehira Y et al. Posttranscriptional regulation of human ABCA7 and its function for the apoA-I-dependent lipid release. Biochem Biophys Res Commun 2003 311 2 313-318 (Pubitemid 37340078)
46. Langmann T, Mauerer R, Zahn A et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 2003 49 2 230-238 (Pubitemid 36143443)
47. Jehle A W., Gardai S J., Li S et al. ATP-binding cassette transporter A7 enhances phagocytosis of apoptotic cells and associated ERK signaling in macrophages. J Cell Biol 2006 174 4 547-556
48. Liang Y, Buckley T R., Tu L, Langdon S D., Tedder T F. Structural organization of the human MS4A gene cluster on chromosome 11q12. Immunogenetics 2001 53 5 357-368 (Pubitemid 32762813)
49. Tateno H, Li H, Schur M J. et al. Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity. Mol Cell Biol 2007 27 16 5699-5710 (Pubitemid 47257827)
50. Crocker P R., Paulson J C., Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007 7 4 255-266 (Pubitemid 46480955)
51. Dustin M L., Olszowy M W., Holdorf A D. et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell 1998 94 5 667-677 (Pubitemid 28427585)
52. Lynch D K., Winata S C., Lyons R J. et al. A cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton. J Biol Chem 2003 278 24 21805-21813 (Pubitemid 36792585)
53. Pimplikar S W., Nixon R A., Robakis N K., Shen J, Tsai L H. Amyloid-independent mechanisms in Alzheimer's disease pathogenesis. J Neurosci 2010 30 45 14946-14954
54. McGeer E G., McGeer P L. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv 2001 1 1 22-29
55. Bates K A., Verdile G, Li Q X. et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009 14 5 469-486
56. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004 3 4 169-176 (Pubitemid 40253499)
57. Rowe J A., Moulds J M., Newbold C I., Miller LHP. P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 1997 388 6639 292-295 (Pubitemid 27317975)
58. Dietschy J M., Turley S D. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001 12 2 105-112 (Pubitemid 32242918)
59. Puglielli L, Tanzi R E., Kovacs D M. Alzheimer's disease: the cholesterol connection. Nat Neurosci 2003 6 4 345-351 (Pubitemid 36373979)
60. Miwa Y, Takiuchi S, Kamide K et al. Insertion/deletion polymorphism in clusterin gene influences serum lipid levels and carotid intima-media thickness in hypertensive Japanese females. Biochem Biophys Res Commun 2005 331 4 1587-1593 (Pubitemid 40692536)
61. Ishikawa Y, Akasaka Y, Ishii T et al. Distribution and synthesis of apolipoprotein J in the atherosclerotic aorta. Arterioscler Thromb Vasc Biol 1998 18 4 665-672 (Pubitemid 28177909)
62. Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb 2011 18 4 274-281
63. Mack J T., Townsend D M., Beljanski V, Tew K D. The ABCA2 transporter: intracellular roles in trafficking and metabolism of LDL-derived cholesterol and sterol-related compounds. Curr Drug Metab 2007 8 1 47-57 (Pubitemid 46043891)
64. Brody D L., Magnoni S, Schwetye K E. et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008 321 5893 1221-1224
65. Shankar G M., Li S, Mehta T H. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008 14 8 837-842
66. Selkoe D J. Alzheimer's disease. Cold Spring Harb Perspect Biol 2011 3 7 pii: a004457
67. Bartl M M., Luckenbach T, Bergner O, Ullrich O, Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Exp Cell Res 2001 271 1 130-141 (Pubitemid 33071000)
68. Bell R D., Sagare A P., Friedman A E. et al. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 2007 27 5 909-918 (Pubitemid 46659038)
69. Stevens B, Allen N J., Vazquez L E. et al. The classical complement cascade mediates CNS synapse elimination. Cell 2007 131 6 1164-1178 (Pubitemid 350235022)
70. Rademakers R, Rovelet-Lecrux A. Recent insights into the molecular genetics of dementia. Trends Neurosci 2009 32 8 451-461
71. Rohrer J D., Guerreiro R, Vandrovcova J et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology 2009 73 18 1451-1456
72. van der Zee J, Sleegers K, Van Broeckhoven C. Invited article: the Alzheimer disease-frontotemporal lobar degeneration spectrum. Neurology 2008 71 15 1191-1197
73. Renton A E., Majounie E, Waite A et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011 72 2 257-268
74. DeJesus-Hernandez M, Mackenzie I R., Boeve B F. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011 72 2 245-256
75. Ballatore C, Lee V M., Trojanowski J Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007 8 9 663-672 (Pubitemid 47283144)
76. Chen-Plotkin A S., Lee V M., Trojanowski J Q. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol 2010 6 4 211-220
77. Mackenzie I R., Rademakers R, Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010 9 10 995-1007
78. Urwin H, Josephs K A., Rohrer J D. et al, FReJA Consortium. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol 2010 120 1 33-41
79. Coppola G, Karydas A, Rademakers R et al. Gene expression study on peripheral blood identifies progranulin mutations. Ann Neurol 2008 64 1 92-96
80. Ghidoni R, Benussi L, Glionna M, Franzoni M, Binetti G. Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 2008 71 16 1235-1239
81. Sleegers K, Brouwers N, Van Damme P et al. Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol 2009 65 5 603-609
82. Geser F, Martinez-Lage M, Robinson J et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009 66 2 180-189
83. Barmada S J., Skibinski G, Korb E, Rao E J., Wu J Y., Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci 2010 30 2 639-649
84. Weihl C C. Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. Curr Alzheimer Res 2011 8 3 252-260
85. Urwin H, Ghazi-Noori S, Collinge J, Isaacs A. The role of CHMP2B in frontotemporal dementia. Biochem Soc Trans 2009 37 Pt 1 208-212
86. Lee J A., Liu L, Gao F B. Autophagy defects contribute to neurodegeneration induced by dysfunctional ESCRT-III. Autophagy 2009 5 7 1070-1072
87. Deng H X., Chen W, Hong S T. et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011 477 7363 211-215
88. Van Deerlin V M., Sleiman P M., Martinez-Lage M et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 2010 42 3 234-239
89. Finch N, Carrasquillo M M., Baker M et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 2011 76 5 467-474
90. Bonifati V. Recent advances in the genetics of dementia with Lewy bodies. Curr Neurol Neurosci Rep 2008 8 3 187-189
91. Clark L N., Kartsaklis L A., Wolf Gilbert R et al. Association of glucocerebrosidase mutations with dementia with Lewy bodies. Arch Neurol 2009 66 5 578-583
92. Brown K, Mastrianni J A. The prion diseases. J Geriatr Psychiatry Neurol 2010 23 4 277-298
93. Mead S, Poulter M, Uphill J et al. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 2009 8 1 57-66
94. Angot E, Steiner J A., Hansen C, Li J Y., Brundin P. Are synucleinopathies prion-like disorders? Lancet Neurol 2010 9 11 1128-1138
95. Kim J, Holtzman D M. Medicine. Prion-like behavior of amyloid-beta. Science 2010 330 6006 918-919
96. Frost B, Diamond M I. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2010 11 3 155-159
97. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser M G. CADASIL. Lancet Neurol 2009 8 7 643-653
98. Ross C A., Tabrizi S J. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011 10 1 83-98
99. Wild E J., Mudanohwo E E., Sweeney M G. et al. Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord 2008 23 5 716-720
100. Stevanin G, Brice A. Spinocerebellar ataxia 17 (SCA17) and Huntington's disease-like 4 (HDL4). Cerebellum 2008 7 2 170-178
101. Garcia-Arocena D, Hagerman P J. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet 2010 19 R1 R83-R89
102. Leehey M A. Fragile X-associated tremor/ataxia syndrome: clinical phenotype, diagnosis, and treatment. J Investig Med 2009 57 8 830-836